#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
High cannabis taxes drive patients and consumers to unregulated illicit markets, where products lack quality testing and may contain contaminants or mislabeled potency, creating safety risks that clinicians should counsel patients about. Clinicians need to understand local tax structures and their market effects to provide realistic harm reduction guidance and inform patients about the actual availability and cost of tested, regulated products in their area. When patients cannot afford legal cannabis due to taxes, they may self-treat with untested substances or delay seeking professional medical guidance, complicating clinical management of conditions like chronic pain or PTSD.
Excessive state cannabis taxation, rather than deterring use, drives consumers toward illicit markets where products lack regulatory oversight and quality assurance, undermining public health protections and tax revenue projections. This economic dynamic creates a two-tiered market in which legal dispensaries compete against untaxed illicit sources, disadvantaging compliant retailers and reducing state tax collection that theoretically funds cannabis regulation and public health programs. For clinicians, the shift toward illicit purchases is clinically significant because unregulated products may contain undisclosed potency levels, contaminants, pesticides, or mold that increase adverse effects and complicate patient counseling about actual cannabinoid exposure. Additionally, patients who purchase from illicit sources lack product traceability and are at higher risk of adverse events that may go unreported to public health authorities, creating blind spots in pharmacovigilance. Policymakers should calibrate cannabis tax rates to remain competitive with illicit pricing while maintaining revenue for regulatory infrastructure and public health initiatives. Clinicians should counsel patients about the risks of illicit cannabis sources and advocate for tax policy that supports access to regulated, tested products as part of comprehensive harm reduction.
“When we price regulated cannabis out of reach through excessive taxation, we’re not eliminating demand—we’re simply redirecting patients back to unregulated sources where we have no control over potency, contaminants, or safety, which undermines the entire public health rationale for legalization in the first place.”
💊 While cannabis taxation policy may seem remote from clinical practice, clinicians should recognize that high tax rates on legal cannabis can inadvertently shift patient consumption toward unregulated illicit products, which pose additional health risks including unknown potency, contaminant exposure, and lack of accurate labeling. This creates a clinical paradox where well-intentioned regulatory measures may worsen patient outcomes by limiting access to tested, quality-controlled products and making it harder for patients to accurately report their actual cannabis use and exposures. The relationship between taxation and illicit market share varies by jurisdiction and depends on multiple factors including enforcement intensity, proximity to lower-tax regions, and baseline consumer preferences, so the magnitude of this effect in any given market requires local context. Clinicians should be aware that patients may be obtaining cannabis from sources beyond the regulated market and should create a non-judgmental space to discuss actual consumption patterns, product types, and potency when taking substance use histories.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: